Genmab A (GMAB) Cash & Current Investments (2018 - 2026)

Genmab A (GMAB) has reported Cash & Current Investments for 9 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments fell 48.15% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (down 48.15% YoY), and the FY2025 full-year result was $1.7 billion, down 12.65% from the prior year.
• Cash & Current Investments fell to $1.5 billion in Q2 2026 per GMAB's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $3.2 billion in Q1 2023 and bottomed at $635.9 million in Q3 2025.
• Historically, Cash & Current Investments has averaged $2.0 billion across 5 years, with a median of $2.1 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments soared 200.55% in 2023, then sank 61.75% in 2025.
• Over 5 years, Cash & Current Investments stood at $879.4 million in 2022, then jumped by 200.55% to $2.6 billion in 2023, then decreased by 25.72% to $2.0 billion in 2024, then retreated by 12.65% to $1.7 billion in 2025, then fell by 12.36% to $1.5 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $1.5 billion, $1.5 billion, and $1.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.